Early Brain Functional Connectivity Changes Induced by Antidepressants and Placebo

Area of Science:

• Neuroscience
• Psychiatry
• Medical Imaging

Background:

• Major depressive disorder (MDD) is a prevalent mental health condition with significant unmet needs for precise treatments.
• Brain imaging studies have identified neural correlates of MDD diagnosis and treatment response, but early circuit-level changes remain elusive.

Purpose of the Study:

• To investigate early changes in functional brain connectivity within the first two weeks of antidepressant or placebo treatment in patients with MDD.
• To differentiate common network alterations from treatment-specific effects and placebo responses.

Main Methods:

• Analysis of functional connectivity in two independent cohorts of MDD patients undergoing treatment.
• Utilized brain imaging techniques to examine neural network engagement during early treatment phases.
• Employed a placebo response prediction model to analyze treatment outcomes.

Main Results:

• A consistent increase in functional connectivity within the visual-precuneus-thalamus network was observed across all patients, irrespective of treatment.
• Placebo response was associated with alterations in attention and striatal systems.
• Drug-specific effects, localized to the amygdala, mid-cingulate, orbitofrontal cortex, and cerebellum, emerged in a subset of medicated patients.
• A placebo response prediction model successfully predicted outcomes for patients without drug-specific changes.

Conclusions:

• Early functional connectivity changes provide insights into both shared and distinct mechanisms underlying MDD treatment response.
• Identified specific neural circuits modulated by antidepressants versus placebo.
• Findings suggest potential for personalized interventions based on early neurobiological markers in MDD.